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MicroRNA (miRNA) control has emerged as a critical regulatory principle in the mammalian immune 
system. Genetic ablation of the miRNA machinery, as well as loss or deregulation of certain 
individual miRNAs, severely compromises immune development and response and can lead to 
immune disorders like autoimmunity and cancer. Although individual miRNAs modulate protein 
output from hundreds of target genes, they may impact physiological processes by regulating 
the concentrations of just a few key cellular proteins that may be components of a single or of 
functionally interrelated pathways in a given cellular context.Introduction
The generation of the mammalian immune system from 
hematopoietic stem cells (HSCs) involves ordered events of 
lineage commitment, differentiation, proliferation, and cell 
migration. This includes developmental programs of ordered 
immunoglobulin (Ig) and T cell receptor (TCR) gene segments 
to equip each lymphocyte with a single antigen receptor—
BCR in the case of B cells, and TCR in the case of T cells. It 
also includes the differentiation of the cells into distinct cel-
lular subsets with distinct effector functions, and innate and 
adaptive responses to antigens, in which cell interactions 
between lymphocytes of different subsets and of lymphocytes 
with other cells of the hematopoietic system such as dendritic 
cells play a critical role and which may be accompanied by the 
generation of immunological memory. Because of its unique 
experimental accessibility, this system is perhaps the best-
characterized developmental system in mammals, in terms of 
surface markers of cell subsets and of signaling pathways and 
transcriptional programs underlying developmental progres-
sion, cellular selection, and cell migration. The immune system 
has also been well characterized with respect to differentiation 
processes and effector mechanisms involved in acquired and 
innate immune responses.
Given the detailed conceptual and experimental frame-
work of our present understanding of the immune system, 
it came as a surprise that there is a previously unrecog-
nized layer of control impacting at least some of the salient 
features of the development and physiology of the system, 
namely control exerted by microRNAs (miRNAs). miRNAs are 
endogenously encoded single-stranded RNAs of about 22 
nt in length that play essential roles in animals and plants, in 
a large variety of physiological contexts (Ambros, 2004; Bar-
tel, 2004; Bushati and Cohen, 2007). Hundreds of miRNAs, 
many of them evolutionarily conserved, have been identified 
in mammals (miRBase, http://microrna.sanger.ac.uk/), and 
many of these molecules exhibit highly specific, regulated 
patterns of expression (Chen et al., 2004; Landgraf et al., 26 Cell 136, January 9, 2009 ©2009 Elsevier Inc.2007; Merkerova et al., 2008; Monticelli et al., 2005; Neilson 
et al., 2007), which can be transcriptionally or posttranscrip-
tionally controlled. Many miRNAs derive from independent 
transcription units, but miRNA genes can also be located in 
the introns of protein-coding genes (Rodriguez et al., 2004). 
A large fraction of miRNAs are clustered in the genome, with 
arrangement and expression patterns suggesting that they 
are transcribed as polycistronic primary transcripts (Bar-
tel, 2004). The primary transcript of a miRNA gene, the pri-
miRNA, is cleaved by the RNAase III endonuclease Drosha 
in the nucleus, to release a 60–70 nt stem-loop intermediate, 
known as the pre-miRNA. The pre-miRNA is subsequently 
exported to the cytoplasm, where it is further cleaved by 
Dicer, another RNase III endonuclease, to produce a dou-
ble-stranded RNA duplex, which contains the mature miRNA 
and its antisense strand. The Dicer cleavage process is cou-
pled with the integration of the mature miRNA into the RNA-
induced silencing complex (RISC), whose core components 
are the Argonaute family proteins (Ago1–4). The miRNA 
then directs the RISC to its target mRNA, which it recog-
nizes through partial sequence complementarity. A major 
determinant in this recognition process is a perfect match 
in the so-called seed region of 6–8 nt at the 5′ end of the 
miRNA. The usual consequence of miRNA:mRNA interaction 
is the downregulation of protein expression by translational 
repression, mRNA cleavage, or promotion of mRNA decay 
(Kim, 2005). Recent proteomic experiments in mammalian 
cells have demonstrated that single miRNAs can directly 
repress the production of hundreds of proteins, that repres-
sion is typically mild, and that it is mostly, but not always, 
due to both downregulation of mRNA levels and translation 
inhibition (Baek et al., 2008; Selbach et al., 2008). There is 
some evidence that under certain conditions miRNAs can 
also upregulate the translation of target mRNAs (Vasudevan 
et al., 2007) or even directly interfere with gene transcription 
(Kim et al., 2008). The physiological impact of such modes 
of regulation remains to be determined.
Below, we discuss studies of the immune system, exemplify-
ing that this multitarget, subtle mode of control turns out to be 
highly efficient and versatile in mammalian cells, through the 
targeting of multiple components of regulatory networks inside 
the cell. In this context, a special aspect of miRNA control is 
of particular interest, namely its rapid evolvability. Because of 
their simple structure and mode of target recognition, miRNAs 
as well as their targets can evolve rapidly (Chen and Rajewsky, 
2007; Gardner and Vinther, 2008; Lu et al., 2008; Niwa and 
Slack, 2007). As rapid evolution is a characteristic feature and 
essential element of the interplay of the immune system with 
pathogens, one might thus predict that miRNAs may play a 
prominent role in the control of host-pathogen interactions 
and that the immune system may thus offer particularly rich 
opportunities to study mechanisms of miRNA control. Emerg-
ing experimental evidence supports this view.
In our discussion, we mainly focus on experiments in which 
genetic evidence obtained in vivo provides unequivocal evi-
dence for the impact of miRNA control.
miRNAs Control Development and Responses of the 
Immune System
After a first demonstration that overexpression of a miRNA in 
HSCs affected B lymphopoiesis in vivo upon HSC transplan-
tation (Chen et al., 2004), it became apparent from experi-
ments in which Dicer, the key enzyme in miRNA biogenesis, 
was conditionally inactivated in T or B lymphocytes of the 
mouse that miRNAs are critical for lymphocyte development 
and differentiation. In the case of T cell development, dele-
tion of Dicer in immature thymocytes (at the so-called double 
negative 3 [DN3] stage) led to a 10-fold reduction in total thy-
mocyte numbers, with a drastic reduction of the more mature 
double-positive (CD4+CD8+) and single-positive (CD4+ or 
CD8+) thymocytes, probably because of increased cell death. 
Although very few peripheral T cells were detectable in these 
animals (Cobb et al., 2005), the peripheral CD4+ T cells were 
only reduced 2-fold when Dicer was deleted at the double-
positive stage of thymocyte differentiation. The mutant cells 
exhibited reduced proliferation and increased cell death upon 
activation in vitro. When cultured under conditions that favor 
differentiation toward T helper 1 (Th1) and Th2 lineages, they 
showed a bias toward Th1 differentiation, reflecting the failure 
of these cells to repress interferon γ (IFNγ) expression (Muljo 
et al., 2005). The T cell subset most affected by the dele-
tion of Dicer at the double-positive stage are the T regulatory 
cells, whose 6-fold reduction in both thymus and periphery 
likely resulted in the severe immunopathology developing in 
the mutant mice, characterized by splenomegaly, enlarged 
intestinal lymph nodes, and colitis (Cobb et al., 2006). That 
miRNAs are essential for the homeostasis and suppressor 
function of T regulatory cells was corroborated by Dicer and 
Drosha deletion in those cells and the ensuing fatal autoim-
munity indistinguishable from that caused by deficiency in 
Foxp3, the master transcription factor controlling regulatory 
T cell differentiation (Chong et al., 2008; Liston et al., 2008; 
Zhou et al., 2008). Regulatory T cells require stronger signals 
from their TCR to be positively selected than do T cells of 
other subsets (Zheng and Rudensky, 2007), hinting at the possibility that miRNAs may be involved in the control of the 
sensitivity of T cells to signals from the TCR. As discussed 
further below, this seems indeed to be the case.
That a deficiency in miRNAs also affects B cell develop-
ment was first suggested by the conditional deletion of Ago2, 
a component of RISC, in hematopoietic cells, which resulted 
in a partial deficiency in miRNAs and compromised develop-
ment of B and erythroid cells (O’Carroll et al., 2007). When 
Dicer was deleted in the B cell lineage from the earliest stage 
of B cell development, an almost complete block at the pro- 
to pre-B transition resulted, which was at least in part due 
to apoptosis of Dicer deficient pre-B cells (Koralov et al., 
2008). In an attempt to elucidate the molecular basis of this 
phenotype, gene expression profiles of Dicer deficient and 
proficient pro-B cells were established, and a bioinformatic 
search was conducted for conserved nucleotide hexamers 
complementary to miRNA seed regions in the 3′ untrans-
lated regions (UTRs) of genes upregulated in Dicer deficient 
pro-B cells. Surprisingly, only a few such motifs were identi-
fied, with a corresponding small group of miRNAs predicted 
to be critical players at the pro-B cell stage. Most of these 
miRNAs belonged to three interrelated miRNA clusters, one 
of which, miR-17?92, has emerged as a critical regulator of 
cellular development in a variety of cellular contexts, as will 
be further discussed below. The six miRNAs encoded in the 
miR-17?92 cluster share four distinct seed regions, and when 
the annotated 3′ UTRs of genes in the mouse were grouped 
according to the number of corresponding conserved target 
sites, two genes on top of the list were immediately appar-
ent as potentially causally involved in the induction of apop-
tosis in Dicer deficient pre-B cells: the genes encoding the 
proapoptotic Bcl2 family member Bim and the tumor sup-
pressor Pten, which can positively control Bim expression. 
When this bioinformatic prediction was tested, Bim and Pten 
were indeed found to be strongly upregulated in Dicer-defi-
cient B cell progenitors, and, most importantly, B cell devel-
opment could be partially rescued by transgenic Bcl2 or Bim 
deficiency (Koralov et al., 2008).
These experiments exemplify a way to identify miRNAs and 
their targets in a particular biological context by combining bio-
informatic and experimental approaches and also reveal that 
targeting of multiple components of a regulatory network as one 
of the emerging principles of miRNA control. This latter notion 
will be discussed in more detail below. In a broader sense, how-
ever, the inactivation of components of the miRNA machinery 
in lymphocytes has made us realize that although miRNA con-
trol does not seem to affect lymphocyte development in every 
respect—V(D)J recombination, for example, appears to func-
tion properly in Dicer deficient B cells in a first approximation—
it operates at multiple levels in lymphocyte development and 
physiology and will have to be studied separately for individual 
miRNAs. It is important to keep in mind in this context that Dicer 
ablation by conditional gene targeting may well fail to uncover 
miRNA control in certain situations because of the persistence 
of Dicer protein or of miRNAs (whose decay in cells is known to 
vary substantially between individual miRNA species) after Dicer 
gene deletion (Cobb et al., 2005; Koralov et al., 2008; Muljo et 
al., 2005; Ramachandran and Chen, 2008). On the other hand, Cell 136, January 9, 2009 ©2009 Elsevier Inc. 27
Dicer deficiency may reveal functions of this enzyme outside of 
miRNA control, such as transcriptional gene silencing through 
the production of endogenous small interfering RNAs (siRNAs). 
Silencing of centromeric repeats through such a mechanism 
has been demonstrated in yeast (Verdel et al., 2004; Volpe et al., 
Figure 1. The miR-150-c-Myb Interaction
(A) A primary target of miR-150 is the proto-oncogene c-Myb. Ratios of 
miR-150/U6 and c-Myb/β-actin are shown for thymocytes of miR-150 trans-
genic mice. TG1–4 are four transgenic mouse strains with different miR-150 
expression levels. The miR-150/U6 ratio in wild-type CD4+ T cells and c-Myb/
β-actin ratio in wild-type thymocytes are set as 1.
(B) The splenic B cell numbers in miR-150 transgenic mice. The transgenic 
mice exhibited a dose-dependent developmental block at the pro- to pre-B 
transition and a reduction of splenic B cell numbers at young age. Each dot 
represents the average of multiple mice at similar age. Adapted from Xiao et 
al. (2007).28 Cell 136, January 9, 2009 ©2009 Elsevier Inc.2002), and there was indeed an indication in Dicer-deficient B 
cells for a derepression of a set of D elements in the IgH locus, 
which exhibit a similar repeat structure (Chakraborty et al., 2007; 
Koralov et al., 2008). Whether Dicer dependent mechanisms of 
epigenetic gene silencing play a significant role in mammalian 
cells remains to be elucidated.
That the genetic inactivation of individual mammalian miRNAs 
can produce discernible phenotypes became apparent early 
in 2007 from four papers (Rodriguez et al., 2007; Thai et al., 
2007; van Rooij et al., 2007; Zhao et al., 2007), two of which 
addressed a miRNA specifically expressed in the hematopoi-
etic system. Like most other cells, cells in the hematopoietic 
system express a multitude of miRNA species, which may 
or may not be shared between different cell types or devel-
opmental stages, but only a few of which are specific for the 
hematopoietic system (Merkerova et al., 2008; Monticelli et 
al., 2005; Neilson et al., 2007; Wu et al., 2007). Knockout of a 
miRNA of the latter kind, miR-155, affected a large spectrum 
of immune reactions, ranging from cytokine production by T 
and B cells to antigen presentation by dendritic cells and the 
germinal center B cell response (Rodriguez et al., 2007; Thai et 
al., 2007). There is also evidence that miR-155, together with 
others, is involved in the control of innate immune reactions. 
Expression profiling showed that stimulation of monocytes with 
lipopolysaccharide (LPS) induced the expression of miR-132, 
miR-146, and miR-155 (O’Connell et al., 2007; Taganov et al., 
2006). miR-146 targets Traf6 and Irak1, components of the Toll-
like receptor (TLR) signaling pathway that is activated by LPS, 
suggesting a negative feedback loop (Taganov et al., 2006). 
The functional importance of LPS-induced miR-155 expres-
sion in myeloid cells was further supported by the work of Tili 
et al. (2007), and the myeloproliferative disorder that develops 
in mice reconstituted with bone marrow progenitors that had 
been retrovirally transduced to express miR-155 (O’Connell 
et al., 2008). Induction of miR-155 expression by LPS could 
thus be a mechanism through which the immune system rap-
idly expands the myeloid cell population during inflammatory 
responses (O’Connell et al., 2008).
Other miRNAs control additional processes in the immune 
system. Thus, genetic ablation of miR-150 led to the expan-
sion of the B1 B cell subset, involved in natural defense against 
pathogens, in spleen and peritoneal cavity, increased steady-
state serum immunoglobulin levels, and enhanced T-depen-
dent immune responses (Xiao et al., 2007). miR-181 seems 
to control TCR signaling thresholds in T lymphocytes, as dis-
cussed further below, and may also participate in the control 
of the antibody response (Li et al., 2007; de Yébenes et al., 
2008). miR-223 is a myeloid-specific miRNA whose deletion 
leads to an increase in the numbers of neutrophil progenitors 
and mature neutrophils, as well as an increased neutrophil 
response to fungal infection, demonstrating that this miRNA 
plays important roles in the development and function of the 
myeloid lineage and innate immunity (Johnnidis et al., 2008).
Taking these findings together, miRNA control has emerged 
as a general regulatory mechanism in immune development 
and the acquired and innate immune response. In the sections 
below, we focus on what is known about mechanisms by which 
miRNAs exert their function.
Dose-Dependent Modulation of Key Targets by miRNAs
Studies are now revealing that miRNAs modulate the con-
centration of key target proteins over a narrow range in a 
dose-dependent manner. In general, the net outcome of 
miRNA binding to its target mRNAs is a reduction of the 
amounts of protein produced from these mRNAs (Baek et 
al., 2008; Selbach et al., 2008). Addressing this issue quan-
titatively, Xiao et al. (2007) studied the interaction between 
miR-150 and its chief target, c-Myb, in the context of lym-
phocyte development in vivo. miR-150 is highly expressed 
in mature B and T cells but not in their progenitors, whereas 
c-Myb is highly expressed in lymphocyte progenitors but 
downregulated upon maturation. Genetic studies had dem-
onstrated that c-Myb plays a critical role at multiple stages 
of lymphocyte development, including the transition from 
pro- to pre-B cells (Bender et al., 2004; Thomas et al., 2005). 
When miR-150 was ectopically expressed at graded con-
centrations in lymphocyte progenitors in vivo, with the high-
est concentration at about 55% of that in mature wild-type 
CD4+ T cells, a dose-dependent downregulation of c-Myb 
protein levels was observed, with a 35% reduction caused 
by the highest concentration of the transgenic miRNA. The 
transgenic mice exhibited a dose-dependent developmen-
tal block at the pro- to pre-B transition and a reduction of 
splenic B cell numbers at young age (Figure 1). That the 
developmental block was mainly caused by the reduction 
in c-Myb protein levels was supported by a similar pheno-
type in c-Myb heterozygous mice, which displayed a similar 
reduction of c-Myb levels in B cell progenitors.
These experiments suggested a few basic principles of the 
relationship between miRNAs and their target genes. First, 
the cellular concentration of a miRNA dictates the protein 
output of its target genes and is therefore of key importance 
in miRNA-mediated control. Second, small changes in the 
concentration of key cellular proteins as effected by miRNA 
control can have significant biological consequences, in 
line with the many examples of pathogenic hemizygous 
null mutations in man and mouse (Santarosa and Ash-
worth, 2004; Seidman and Seidman, 2002; Smilenov, 2006). 
miRNAs may have evolved to modulate the concentrations 
of such key cellular proteins. Third, although a single miRNA 
can repress protein production from hundreds of genes, 
only a few of these proteins may be critical for a particular 
biological process.
In studies in Caenorhabditis elegans and Drosophila mela-
nogaster, the control of single key target genes also appeared 
to largely explain the functions of individual miRNAs (Karres 
et al., 2007; Lee et al., 1993; Teleman et al., 2006; Varghese 
and Cohen, 2007; Wightman et al., 1993). As in the case of 
miR-150 in mice, these claims were largely based on the 
similarity between the phenotypes caused by loss- and/or 
gain-of function of individual miRNAs and manipulating the 
protein levels of target genes to similar degrees. This clearly 
leaves room for a contribution of additional target genes to 
the observed phenotypes. Targeted mutagenesis of miRNA 
binding sites in target mRNAs is ultimately required to directly 
address this issue, as exemplified further below for miR-155 
and its target gene AID.Setting Signaling Thresholds by Modulating Negative 
Regulators: miR-181
To accommodate the differential needs of developing and 
mature T cells in their response to antigen (the former being 
positively and negatively selected by self-antigens, the latter 
responding to foreign antigens), thymocytes exhibit a higher 
sensitivity than mature T cells to the signal triggered by TCR 
engagement of peptide-MHC complexes. This is despite the 
fact that the TCR uses the same set of molecules for signal-
ing at different developmental stages (Germain and Stefanova, 
1999). Recent experiments indicate that miR-181 is critically 
involved in this developmental control, through its predomi-
nant expression in thymocytes and its ability to downregulate 
the protein levels of multiple phosphatases that are negative 
regulators of distinct steps of the TCR signaling pathway (Li et 
al., 2007) (Figure 2). The protein tyrosine phosphatase PTPN22 
dephosphorylates and inactivates Lck and ZAP70, two crucial 
components of proximal TCR signaling (Wu et al., 2006). Dual 
specificity phosphatases DUSP5 and DUSP6 dephosphory-
late and inactivate the kinase ERK, with the former acting in 
the nucleus and the latter acting in the cytoplasm (Owens and 
Keyse, 2007; Tanzola and Kersh, 2006). ERK1 and ERK2 are 
essential for the positive selection of double-positive thymo-
cytes, and this event is very sensitive to the dosage of ERK 
activity. Targeted deletion of both ERK1 and ERK2 leads 
to a complete block of positive selection, whereas retroviral 
expression of a dominant-negative mutant of DUSP6, which 
increases ERK activity, enhances positive selection (Bettini and 
Kersh, 2007; Fischer et al., 2005). Overexpression of miR-181 
in mature T cells similarly increases ERK activity, and this con-
Figure 2. miR-181 Sets Signaling Thresholds by Modulating 
 Multiple Negative Regulators
miR-181 is highly expressed in double positive (CD4+CD8+) thymocytes and 
downregulated upon T cell maturation. By downregulating the concentra-
tions of several negative regulators of TCR signaling, miR-181 changes the 
outcome of signaling triggered by TCR engagement by peptide-MHC com-
plexes: double-positive thymocytes, but not mature T cells, respond to self-
antigens and are positively or negatively selected.Cell 136, January 9, 2009 ©2009 Elsevier Inc. 29
verts antagonist peptides into agonists. 
Treatment of thymocytes with antago-
mir-181, which degrades its endogenous 
counterpart, reduces ERK activity and 
impairs positive selection of thymocytes 
in a fetal thymic organ culture system (Li 
et al., 2007).
Significantly, the regulation of the 
response of T cells to signals from the 
TCR by miR-181 could not be fully reca-
pitulated by knockdown of the protein 
levels of any one of its proposed targets 
with shRNAs, whereas restoration of the 
protein levels of individual targets partly 
or completely reversed the effects of 
miR-181 overexpression. This suggests 
that the repression of a given target was 
essential but not sufficient for the func-
tion of miR-181 (Li et al., 2007).
Although these experiments still await 
confirmation in vivo, they suggest that 
miRNAs may target multiple compo-
nents in a common regulatory pathway, 
a concept that is also supported by the functional analysis of 
miR-155 and the miR-17?92 cluster (see below). Conceptually 
similar to the additive effect on tumor development of double 
heterozygosity of functionally related, mutant tumor suppres-
sor genes (Smilenov, 2006), this regulatory principle may con-
tribute in a major way to the overall impact of miRNA control, 
despite moderate effects on the concentrations of individual 
target proteins.
Nonsynergistic Control of Distinct Regulatory Pathways: 
miR-155
Genetic gain- and loss-of function studies of miR-155, which 
is upregulated in B and T cells upon activation, have demon-
strated that this miRNA plays a positive role in the control of 
the germinal center reaction in vivo, in addition to its mani-
fold other regulatory roles (Rodriguez et al., 2007; Thai et 
al., 2007; Vigorito et al., 2007). Curiously, a potential target 
of this miRNA is the enzyme AID, a central player in the ger-
minal center reaction, mediating class switch recombination 
(CSR) and somatic hypermutation (SHM) (Chaudhuri and 
Alt, 2004; Di Noia and Neuberger, 2007; Honjo et al., 2004). 
AID is also, however, causally involved in oncogenic recipro-
cal translocations between IgH and c-myc (c-myc-IgH), an 
unwanted byproduct of CSR in the course of the germinal 
center reaction (Muramatsu et al., 2000; Ramiro et al., 2004). 
This calls for a careful control of AID activity during this pro-
cess. To analyze whether miR-155 is involved in this control, 
a knockin mouse strain carrying a mutation in the evolution-
ary conserved miR-155 binding site in the 3′ UTR of the AID 
gene was generated (Dorsett et al., 2008). AID protein levels 
were increased 2- to 3-fold in both activated miR-155−/− and 
AID155 B cells, demonstrating that AID is a direct target of 
miR-155 in vivo. The latter was also suggested by the work 
of Teng et al. (2008), who made use of a similarly mutated 
AID transgene. Interestingly, although SHM was affected by 
neither the AID gene mutation nor the 
miR-155 knockout, the generation of 
class-switched B cells was increased 
in the former and reduced in the latter 
case. Thus, in miR-155−/− B cells, the 
effect of increased AID protein levels 
on CSR must be offset by changes in 
other target genes. Indeed, the work of 
Vigorito et al. (2007) has shown that the 
protein level of Pu.1, another miR-155 
target gene, is increased in miR-155−/− 
B cells and that this negatively affects 
the differentiation of cells undergoing 
CSR (Vigorito et al., 2007). In contra-
distinction, when c-myc-IgH transloca-
tion was analyzed, activated AID155 B 
cells exhibited a 3- to 6-fold increased 
translocation frequency compared to 
control cells, whereas the transloca-
tion frequency was increased 15-fold 
in miR-155-deficient B cells. Together, 
these data suggested that miR-155 
regulates AID and some additional 
component(s) in a pathway minimizing AID-mediated onco-
genic translocations, and in addition positively controls the 
generation of class-switched B cells in the germinal center 
reaction (Figure 3).
Paradoxically, the latter goes together with downregulation 
of the key mediator of CSR, AID. Perhaps miR-155 had origi-
nally evolved as a safeguard against AID-mediated oncogenic 
translocations and had to accommodate downregulation of 
AID acquired for this purpose in a separate functional context, 
namely the promotion of CSR. The particular risk associated 
with AID expression may also be the reason for its control by 
yet another miRNA, miR-181, perhaps at a different stage of B 
cell activation (de Yébenes et al., 2008).
Cooperation and Redundancy of Coexpressed miRNAs: 
miR-17?92
According to bioinformatic predictions, the 3′ UTRs of miRNA 
target genes often contain binding sites for several differ-
ent miRNAs (Krek et al., 2005; Lewis et al., 2005). On the 
other hand, miRNAs encoded by different genomic loci can 
have very similar mature sequences, and there are families 
of miRNAs sharing seed regions. Can coexpressed miRNAs 
regulate the expression of target mRNAs in a cooperative man-
ner? Do members of the same miRNA family regulate different 
sets of targets, because of sequence differences outside the 
seed region, or are they functionally redundant? Recent stud-
ies of the miR-17?92 cluster and related miRNA clusters begin 
to answer some of these questions.
The miR-17?92 transcript encoded by mouse chromosome 
14 is the precursor of six miRNAs (miR-17, miR-18a, miR-19a, 
miR-20a, miR-19b, and miR-92, not including miR-17*). Addi-
tionally, this cluster is homologous to the miR-106a?363 
cluster on the X chromosome and the miR-106b?25 cluster 
on chromosome 5. Together, these three clusters contain 15 
miRNA stem-loops, giving rise to 13 distinct mature miRNAs, 
Figure 3. miR-155 Controls Distinct 
 Regulatory Pathways
miR-155 controls the generation of class-switched 
B cells and c-myc-IgH translocations. In the former 
case, miR-155 downregulates AID, an essential en-
zyme for class switch recombination (CSR), and the 
transcription factor Pu.1, which counteracts the dif-
ferentiation of class-switched cells. The net effect, 
possibly involving additional miR-155 targets, is the 
promotion of this process. As for c-myc-IgH trans-
locations, miR-155 downregulates AID and other 
target genes, which synergize with AID in mediating 
these events.30 Cell 136, January 9, 2009 ©2009 Elsevier Inc.
Figure 4. miR-17?92 Regulates Functionally Interrelated Pathways
(A) The genomic organization of miR-17?92 and homologous clusters. miRNAs of the same color have identical seed regions (nucleotides 2–7). The miR-
106b?25 cluster resides in an intronic region of the Mcm7 gene.
(B) Alignment of mature miRNA sequences. Bold letters indicate seed regions.
(C) miR-17?92 regulates components of functionally interrelated pathways. miRNA targets are indicated in bold. Pten is an inhibitor of the PI3K pathway, which 
promotes cell cycle progression, and inhibits apoptosis by negatively regulating the transcription of Bim, a proapoptotic factor and itself a miR-17?92 target. 
p21 is an inhibitor of G1/S cell cycle transition. The miR-17?92 cluster also targets Rbl2, a member of the Rb family of pocket proteins that negatively regulate 
cell cycle, and E2F1, E2F2, E2F3. Whereas a complete loss of the three E2Fs blocks G1/S transition, mice with compound mutations of E2F1 and E2F2 develop 
lymphomas.which fall into four miRNA families (miR-17, miR-18, miR-19, 
and miR-25) (Figures 4A and 4B). This genomic organization 
is highly conserved in all vertebrates from which complete 
genome sequences are available (Tanzer and Stadler, 2004). 
The miR-17?92 and miR-106b?25 clusters are ubiquitously 
expressed, whereas expression of the miR-106a?363 clus-
ter was undetectable in the tissues examined (Ventura et al., 
2008). During lymphocyte development, miR-17?92 miRNAs 
are highly expressed in progenitor cells, with the expression 
level decreasing 2- to 3-fold upon maturation (Ventura et al., 
2008; Xiao et al., 2008).
Addressing the biological functions of these miRNAs, Ven-
tura and colleagues (2008) showed that although deficiency of 
miR-106a?363 or miR-106b?25 did not produce a detectable 
phenotype, mice deficient of miR-17?92 were 40% smaller 
than their wild-type littermates and died within minutes after 
birth, because of lung hypoplasia and a ventricular septal 
defect of the heart. In the hematopoietc system, there was a 
severe block of B cell development at the pro- to pre-B transi-
tion, with increased apoptosis of pro-B cells. When both the 
miR-17?92 and miR-106b?25 cluster were deleted, the mice 
died before embryonic day 15, with the mutant embryos dis-
playing severe cardiac developmental abnormalities and apop-
tosis in specific regions of the central nervous system and the 
fetal liver. The B cell developmental block also became more severe in the absence of these two miRNA clusters (Ventura et 
al., 2008). This demonstrates functional cooperation between 
the two miRNA clusters.
In humans, the miR-17?92 miRNA cluster is located at chro-
mosome 13q31, a genomic region that is frequently amplified in 
lymphomas and solid tissue cancers, and the mature miRNAs 
encoded by this locus are expressed in high amounts in those 
cancer cells (Hayashita et al., 2005; Lu et al., 2005; Ota et al., 
2004; Tagawa and Seto, 2005; Zhang et al., 2007). He and col-
leagues showed that retroviral expression of miR-17?92 on 
the Eµ-Myc transgenic background accelerated c-Myc-medi-
ated lymphomagenesis (He et al., 2005). To address whether 
miR-17?92 overexpression by itself can reproduce some of 
these pathologies, we generated transgenic mice expressing 
the human miR-17?92 cluster specifically in B and T lympho-
cytes, at levels comparable to those found in human lymphoma 
cell lines, to study the consequences of elevated miR-17?92 
expression (Xiao et al., 2008). The mutant mice exhibited spon-
taneous activation and pronounced expansion of B and T lym-
phocytes, as well as symptoms typical of lymphoproliferative 
and autoimmune disease, and died prematurely. Lymphoma 
development may have been precluded in the animals simply 
because of their short life span. Reporter assays in cell culture 
revealed that, as predicted bioinformatically, (see Koralov et al., 
2008), Pten and Bim were functional targets of miRNAs in the Cell 136, January 9, 2009 ©2009 Elsevier Inc. 31
miR-17?92 cluster. Indeed, mice doubly heterozygous for Pten 
and Bim partly reproduced the phenotype of the miR-17?92 
transgenics, demonstrating that downregulation of Pten and 
Bim did contribute to the transgenic phenotype, but deregula-
tion of other targets must also be involved (Xiao et al., 2008). 
Such additional targets have been identified in other cellular 
contexts, as discussed below.
These studies demonstrated additional principles of miRNA 
control. First, homologous miRNAs with similar expression pat-
terns can be functionally redundant, as exemplified by the lack of 
an obvious phenotype in mice deficient for miR-106b?25, whose 
function is apparently largely compensated by miR-17?92. (The 
phenotypic difference caused by deletion of miR-17?92 and 
miR-106b?25 may be due to the fact that only the miR-17?92 
cluster contains members of the miR-18 and miR-19 families). 
Previous studies of the let-7 family of miRNAs in C. elegans 
came to a similar conclusion (Abbott et al., 2005). Second, there 
is a dose effect among coexpressed homologous miRNAs, as 
demonstrated by the more severe phenotype produced by com-
bined miR-17?92 and miR-106b?25 deficiency than produced 
by miR-17?92 deficiency alone. Third, miRNAs organized in a 
cluster can regulate not only multiple components of a single 
pathway but also components of functionally interrelated path-
ways. Thus, miR-17?92 miRNAs target Pten and Bim in the PI3K 
pathway (Xiao et al., 2008), and a few critical cell cycle regula-
tors (such as p21, Rbl2, E2F1, E2F2, and E2F3), as suggested 
by studies in various cellular contexts (Lu et al., 2007; O’Donnell 
et al., 2005; Petrocca et al., 2008; Sylvestre et al., 2007; Wang 
et al., 2008) (Figure 4C). P21, Rbl2, E2F1, E2F2, and E2F3 regu-
late cell cycle progression at the G1 to S transition (Balomenos 
et al., 2000; Cobrinik, 2005; Field et al., 1996; Massague, 2004; 
Murga et al., 2001; Santiago-Raber et al., 2001; Yamasaki et al., 
1996; Zhu et al., 2001). The PI3K pathway promotes cell cycle 
progression through at least two mechanisms: (1) AKT-mediated 
inactivation of GSK3β, which phosphorylates and destabilizes 
cyclin D, an essential cyclin for the G1 to S transition, and (2) 
AKT-mediated phosphorylation of FOXO transcription factors, 
and their subsequent translocation to the cytoplasm from the 
nucleus, where they drive transcription of p21 and p27, two neg-
ative regulators of the G1 to S transition (Manning and Cantley, 
2007). The net outcome of regulating these targets is enhanced 
cell survival and proliferation. Finally, there was an indication 
that coexpressed miRNAs can regulate a common target in a 
cooperative manner, in accord with earlier work in cell culture 
systems (Doench and Sharp, 2004; Grimson et al., 2007; Krek 
et al., 2005). In the case of the control of Pten by miR-17 and 
miR-92, the upregulation of a reporter gene containing the Pten 
3′ UTR caused by knockdown of both miR-17 and miR-19 was 
more pronounced than that caused by knockdown of either 
miR-17 or miR-19 alone (Xiao et al., 2008).
miRNAs Control Host-Virus Interactions
As mentioned, the ability of miRNAs and their targets to rap-
idly evolve makes miRNAs ideal candidates for the control of 
host-pathogen interactions, with virus control on the top of the 
list, as viruses entirely depend on the host cellular machinery 
for their survival and propagation. Accordingly, many viruses 
express miRNAs, and a plethora of regulatory mechanisms 32 Cell 136, January 9, 2009 ©2009 Elsevier Inc.is emerging in which host- or virus-encoded miRNAs interact 
with virus or host mRNAs, respectively, in addition to their own 
mRNAs (Scaria et al., 2006).
Viral miRNAs can help viruses to evade the host immune 
response by regulating cellular and viral gene expression 
(Sullivan, 2008). Thus, miR-UL112 encoded by human cyto-
megalovirus (HCMV) downregulates the expression of major 
histocompatibility complex class I-related chain B (MICB), a 
stress-induced ligand of the natural killer (NK) cell activat-
ing receptor (NKG2D) that is critical for the NK cell killing of 
virus-infected cells (Stern-Ginossar et al., 2007). Interestingly, 
the same miRNA binding sites in MICB seem to be exploited 
by cellular miRNAs to maintain the expression of MICB pro-
tein under a certain threshold in normal tissues and to help 
tumor cells to escape immune attack (Stern-Ginossar et al., 
2008). miRNAs encoded by simian virus 40 (SV40) accumu-
late at late stages of infection, are perfectly complementary 
to early viral mRNAs, and target these mRNAs for cleavage. 
This reduces the expression of viral T antigens encoded by the 
early viral mRNAs, enabling the infected cells to evade killing 
by cytotoxic T cells (Sullivan et al., 2005). miRNAs expressed 
by herpes simplex virus 1 (HSV-1) facilitate the establishment 
and maintenance of viral latency through a similar mechanism 
(Umbach et al., 2008).
In turn, cellular miRNAs, in addition to their normal regula-
tory roles, can participate in antiviral defense. Thus, miR-32 
counteracts the accumulation of primate foamy virus type 1 
(PFV-1) in human cells, by directly targeting the PFV-1 genome 
and causing translation inhibition (Lecellier et al., 2005). Some 
viruses overcome miRNA-mediated antiviral defense by encod-
ing proteins that suppress RNA silencing, through mechanisms 
ranging from sequestering small RNAs to disrupting functions 
of key proteins involved in miRNA processing (Haasnoot et 
al., 2007). Viruses can also take advantage of host miRNAs. A 
liver-specific miRNA, miR-122, interacts with sequences in the 
5′ noncoding region of the hepatitis C virus (HCV) RNA, and 
this interaction is required for viral replication and maintains 
high viral RNA abundance in liver cells. The tissue specificity 
of miR-122 expression also helps HCV to establish its tissue 
selectivity (Jopling et al., 2008; Jopling et al., 2005).
Although general rules of miRNA control are unlikely to 
emerge from the analysis of host-virus interactions, such stud-
ies should lead to major new insights into mechanisms of viral 
latency, tropism, and escape from innate and adaptive immune 
responses, and thus potentially new therapeutic approaches.
miRNAs and Hematopoietic Malignancies
Deregulation of miRNA expression has become a recurrent 
theme in the cancer field. Gene expression profiling of human 
cancer cells has revealed specific miRNA expression signa-
tures in many human cancers (Calin et al., 2004a; Lu et al., 
2005). A global downregulation of mature miRNAs was fre-
quently observed in such experiments, often accompanied by 
upregulation of specific groups of miRNAs (Calin and Croce, 
2006; Lu et al., 2005). In addition, miRNA genes are frequently 
located at fragile sites and genomic regions involved in car-
cinogenesis (Calin et al., 2004b), and recent evidence indicates 
that miRNAs can directly contribute to various aspects of this 
process, including tumor metastasis and cancer stem cell 
maintenance (Huang et al., 2008; Kent and Mendell, 2006; Ma 
et al., 2007; Tavazoie et al., 2008; Yu et al., 2007).
miRNAs appear also to be heavily involved in the pathogen-
esis of leukemias and lymphomas. This topic has been recently 
reviewed (Garzon and Croce, 2008), and we limit our discus-
sion in this context to the two cases in which genetic evidence 
in mouse models points to a causal role of miRNAs in these 
diseases. Thus, miR-155 and the miRNAs of the miR-17?92 
cluster (also called oncomir-1) are highly expressed in many 
kinds of human cancers, including lymphomas. Retroviral 
expression of miR-17?92 in mice on the Eµ-myc transgenic 
background accelerated c-Myc-mediated lymphomagenesis 
(He et al., 2005), and transgenic mice with elevated miR-17?92 
expression in lymphocytes died prematurely from a lymphop-
roliferative and autoimmune disease, as discussed earlier (Xiao 
et al., 2008). In the case of miR-155, transgenic mice overex-
pressing this miRNA in B cells developed polyclonal pre-B cell 
proliferation followed by B cell malignancy (Costinean et al., 
2006). In addition, a subset of human patients with acute myel-
oid leukemia (AML) have elevated miR-155 expression in their 
bone marrow, and retroviral expression of miR-155 in bone 
marrow progenitor cells caused a myeloproliferative disorder 
in mice (O’Connell et al., 2008).
Although this field is still in its infancy, the mechanistic study 
of the role of miRNAs in malignancies of the hematopoietic 
system promises not only to lead to a better understanding of 
miRNA control in normal physiology but also to allow the prob-
lem of hematopoietic malignancies to be approached from a 
new clinical angle.
Conclusions
miRNAs have emerged in the immune system as regulatory ele-
ments involved in the control of cellular development, homeo-
stasis, and response in highly specific ways. Key features of 
this control are a dose-dependent regulation of target protein 
concentrations over a mostly modest range and the targeting of 
multiple functionally related proteins. Subtle changes of intrac-
ellular protein concentrations can have profound physiological 
effects as documented by the many pathologies arising from 
haploinsufficiency, and the targeting of several components of a 
functional network may further enhance the functional impact of 
miRNA control. It is therefore not surprising that the genetic abla-
tion as well as ectopic or overexpression of individual miRNAs 
can have severe physiological consequences, ranging, in the 
immune system, from cell death and impairment of immune 
functions to autoimmunity, lymphoproliferation, and cancer.
A major challenge in the field is the identification of the criti-
cal miRNA targets in a particular biological in vivo context. This 
can ultimately only be done by combining bioinformatic, bio-
chemical, and genetic approaches: (1) using bioinformatics to 
predict possible targets and to organize targets into functional 
networks, (2) using proteomic and gene expression analysis, 
as well as reporter assays and the (still challenging) isolation of 
miRNA:mRNA complexes, to identify “real” miRNA targets, and 
(3) using genetic experiments like the overexpression or inac-
tivation of target genes or of miRNA target sequences within 
these genes to address the biological relevance of such targets in a particular biological context. Interdisciplinary approaches 
have thus become indispensable in the pursuit of the biological 
impact of miRNA control.
The unique ability of miRNAs and their target sequences to 
rapidly evolve seems to be reflected in a plethora of miRNA-
based control mechanisms operating in host-virus interac-
tions. In the medical context, this together with the notion that 
miRNAs control, in a dose-dependent manner, cellular states 
or responses rather than single or collections of functionally 
unrelated proteins, makes these molecules attractive candi-
dates or targets for future medical therapies.
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